FDA approves Merck’s Keytruda, Keytruda Qlex for platinum-resistant carcinomas

The Food and Drug Administration approved pembrolizumab, Keytruda from Merck (MRK), as well as pembrolizumab and berahyaluronidase alfa-pmph or Keytruda Qlex from Merck, in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.